Comparative Pharmacology
Head-to-head clinical analysis: CLENPIQ versus CLENZ LYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLENPIQ versus CLENZ LYTE.
CLENPIQ vs CLENZ-LYTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
Colon lavage solution that osmotically induces diarrhea to cleanse the colon.
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
Oral: 4 L (or 240 mL every 10 minutes) administered the evening before colonoscopy; alternatively, 2 L (or 240 mL every 10 minutes) plus 2 L of clear liquids given in split doses (first 1-2 L evening before, remaining in morning of procedure).
None Documented
None Documented
Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component
Not applicable; systemic absorption is negligible (plasma levels below detection limits). Clinical effect is localized to gastrointestinal tract.
Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%)
Primarily fecal (approximately 95%) as unabsorbed polyethylene glycol; negligible renal excretion (<5%) as intact polymer.
Category C
Category C
Laxative
Laxative